Aclaris Therapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ACRS Nasdaq 2830 www.aclaristx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Aclaris Therapeutics, Inc.

Aclaris Therapeutics Begins Phase 1 Clinical Trial for Bispecific Antibody ATI-052 Targeting Inflammatory Diseases - Jul 15th, 2025 6:59 am
Aclaris Therapeutics Added to the Russell 2000® and Russell 3000® Indexes - Jun 30th, 2025 7:31 am
Aclaris Therapeutics to Participate in the H.C. Wainwright Inflammation & Immunology Virtual Conference - Jun 26th, 2025 2:01 pm
Aclaris Therapeutics Initiates Phase 1a/1b Program for its Novel Bispecific Antibody ATI-052 - Jun 23rd, 2025 4:59 am
Aclaris Therapeutics Initiates Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis - Jun 2nd, 2025 4:59 am
Aclaris Therapeutics to Participate in Two June Healthcare Conferences - May 28th, 2025 7:20 am
Aclaris Therapeutics First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag - May 10th, 2025 6:10 am
Aclaris Therapeutics to Participate in the HC Wainwright “HCW@Home” Series - May 9th, 2025 5:00 am
Aclaris Therapeutics (ACRS) Reports Q1 Loss, Misses Revenue Estimates - May 8th, 2025 6:00 am
Aclaris: Q1 Earnings Snapshot - May 8th, 2025 4:57 am
Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - May 8th, 2025 4:50 am
Aclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical Officer - Apr 29th, 2025 5:00 am
Strong week for Aclaris Therapeutics (NASDAQ:ACRS) shareholders doesn't alleviate pain of three-year loss - Apr 25th, 2025 6:16 am
Aclaris Therapeutics receives FDA approval for Phase Ia/Ib trial of ATI-052 - Apr 23rd, 2025 4:44 am
Aclaris Therapeutics Secures U.S. Food and Drug Administration IND Clearance for ATI-052, Enabling Advancement of its Novel Bispecific Anti-TSLP/IL-4R Investigational Antibody - Apr 22nd, 2025 4:59 am
Will Aclaris Therapeutics (NASDAQ:ACRS) Spend Its Cash Wisely? - Mar 31st, 2025 6:18 am
Aclaris Therapeutics assumed with an Overweight at Cantor Fitzgerald - Mar 19th, 2025 6:21 am
Aclaris Therapeutics to Participate in Two March Healthcare Conferences - Mar 4th, 2025 5:00 am
This Aclaris Therapeutics Insider Increased Their Holding By 1,537% Last Year - Mar 4th, 2025 4:46 am
Aclaris Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Mar 4th, 2025 4:21 am